首页CGEN • NASDAQ
add
Compugen Ltd
昨日收盘价
$2.43
当日价格范围
$2.26 - $2.41
年度波幅
$1.35 - $3.03
市值
2.02亿 USD
平均交易量
86.98万
市盈率
117.89
股息率
-
主要交易所
NASDAQ
相关资讯
财务信息
损益表
收入
净收入
(USD) | 2024年9月info | 年同比变化 |
---|---|---|
收入 | 1713.20万 | — |
经营支出 | 903.50万 | -14.99% |
净收入 | 127.60万 | 112.95% |
净利润率 | 7.45 | — |
每股收益 | 0.01 | 109.09% |
息税折旧摊销前利润 | 461.50万 | 143.92% |
有效税率 | 77.92% | — |
资产负债表
总资产
负债总额
(USD) | 2024年9月info | 年同比变化 |
---|---|---|
现金及短期投资 | 1.13亿 | 95.99% |
总资产 | 1.24亿 | 82.69% |
负债总额 | 6302.80万 | 338.18% |
权益总额 | 6048.80万 | — |
发行在外的股份 | 8953.57万 | — |
市净率 | 3.57 | — |
资产回报率 | 9.62% | — |
资本回报率 | 18.01% | — |
现金流
现金净变动
(USD) | 2024年9月info | 年同比变化 |
---|---|---|
净收入 | 127.60万 | 112.95% |
来自运营的现金 | — | — |
投资现金 | — | — |
融资现金 | — | — |
现金净变动 | — | — |
自由现金流 | — | — |
简介
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors. Wikipedia
CEO
成立时间
1993年2月10日
网站
员工数量
68